Biotechnology company developing programmable immune-system therapeutics using engineered immune “attack particles” that deliver cancer-killing proteins such as granzymes and perforins
Biotechnology company developing programmable immune-system therapeutics using engineered immune “attack particles” that deliver cancer-killing proteins such as granzymes and perforins. The platform aims to target cancer cells while sparing healthy tissue, with potential applications in oncology, autoimmune disease, and infections.